Document Detail

Control of pituitary adenoma cell proliferation by somatostatin analogs, dopamine agonists and novel chimeric compounds.
MedLine Citation:
PMID:  17413185     Owner:  NLM     Status:  MEDLINE    
The antisecretory effects of somatostatin (SRIH) and its analogs are widely recognized and provide the basis for treatment of hormonal hypersecretion in patients with pituitary adenomas, especially in the settings of acromegaly. Dopamine (DA) agonists have also been used for medical treatment of prolactin and/or GH hypersecretion, and recent evidence points to an even greater antisecretory effect for a chimeric molecule, having high affinity for both SRIH and DA receptors. Evidence for an antiproliferative effect of these compounds has also been provided. This review focuses on the antiproliferative effects of SRIH and its analogs, of DA and chimeric compounds on pituitary adenomas, and on the clinical consequences on tumor volume of pharmacological treatment of pituitary adenomas with these drugs.
Maria Chiara Zatelli; Maria Rosaria Ambrosio; Marta Bondanelli; Ettore C Degli Uberti
Related Documents :
23019305 - Molecular pathways: the metabolic regulator estrogen-related receptor α as a therapeut...
6090975 - The role of dopaminergic mechanisms in mediating the central behavioral effects of morp...
18160635 - Dopamine alters ampa receptor synaptic expression and subunit composition in dopamine n...
7968225 - D2-dopamine agonists inhibit adenosine 3':5'-cyclic monophosphate (camp) production in ...
2553445 - Stimulation by phaclofen of inositol 1,4,5-triphosphate production in cultured neurons ...
12202535 - Ciliary neurotrophic factor as a transient negative regulator of rod development in rat...
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  European journal of endocrinology / European Federation of Endocrine Societies     Volume:  156 Suppl 1     ISSN:  0804-4643     ISO Abbreviation:  Eur. J. Endocrinol.     Publication Date:  2007 Apr 
Date Detail:
Created Date:  2007-04-06     Completed Date:  2007-06-29     Revised Date:  2007-12-19    
Medline Journal Info:
Nlm Unique ID:  9423848     Medline TA:  Eur J Endocrinol     Country:  England    
Other Details:
Languages:  eng     Pagination:  S29-35     Citation Subset:  IM    
Section of Endocrinology, Department of Biomedical Sciences and Advanced Therapies, University of Ferrara, Via Savonarola 9, 44100 Ferrara, Italy.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Acromegaly / drug therapy,  etiology
Adenoma / complications,  drug therapy*
Cell Proliferation / drug effects*
Dopamine Agonists / pharmacology*
Pituitary Neoplasms / complications,  drug therapy*
Receptors, Dopamine / drug effects
Receptors, Somatostatin / drug effects
Somatostatin / analogs & derivatives*,  physiology
Reg. No./Substance:
0/Dopamine Agonists; 0/Receptors, Dopamine; 0/Receptors, Somatostatin; 51110-01-1/Somatostatin
Erratum In:
Eur J Endocrinol. 2007 Oct;157(4):543

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Novel chimeric somatostatin analogs: facts and perspectives.
Next Document:  Novel insights in somatostatin receptor physiology.